

Adherium receives \$1,287,000 Australian R&D Tax Incentive

Melbourne, Australia – 2 December 2022: Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced that it has received \$1,287,000 in cash under the Australian R&D Tax Incentive for the 2022 financial year.

The R&D Tax Incentive is an Australian Government program developed to assist businesses to access refundable tax offsets for expenditure on eligible research and development activities.

Mr Rick Legleiter, Chief Executive Officer, commented, “The support of the Australian Government for in-country R&D initiatives is really appreciated by Adherium and plays an important role in developing our business”.

In the 2022, Adherium continued to directly invest in Australia by recruiting and hiring an internal, predominantly Melbourne-based, software engineering team to progress its research and development roadmap.

Mr. Legleiter continued, “Our research and development project had strong technical challenges worked on by our internal development team as we continue to develop medication adherence solutions”.

- ENDS -

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium’s Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence,



supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: Rick Legleiter
CEO
Adherium Limited
investors@adherium.com